“Medicare’s preliminary decision to limit Part B coverage for the Alzheimer’s drug Aduhelm is good news for beneficiaries. The drug, originally priced at $56,000 per year, contributed to the largest Part B premium increase in recent history, a whopping $21 per month for 2022. Restricting coverage to patients in clinical trials is sound policy, given concerns about Aduhelm’s efficacy and side effects — and will significantly lower Medicare’ costs. This should clear the way for the Biden administration to reduce the 2022 premium increase, which we strongly urged in a letter to the President in December. We are encouraged that HHS Secretary Becerra has now ordered a reassessment of the premium hike. Seniors on fixed incomes should not have to subsidize a questionably effective new drug, grossly overpriced by Big Pharma.” – Max Richtman, President and CEO, National Committee to Preserve Social Security and Medicare
The National Committee, a nonprofit, nonpartisan organization acts in the interests of its membership through advocacy, education, services, grassroots efforts and the leadership of the Board of Directors and professional staff. The work of the National Committee is directed toward developing better-informed citizens and voters.
Media Inquiries to:
Pamela Causey 202-216-8378Walter Gottlieb 202-276-9089